Key result
Age >65 predicts ~370% higher recurrent VTE risk after unprovoked PE, alongside residual obstruction and antibodies.
Population
371 patients with a first unprovoked pulmonary embolism initially treated during 6 months
Comparison
Additional 18 months of warfarin vs Placebo
Design
Cohort, randomised, double-blind
Follow-up
median 41 months
Authors
Loading...
May support risk stratification for anticoagulation duration after unprovoked PE; leaves open need for prospective validation.
RCT (n=371)
double-blind
randomised
Effect estimate: HR 4.70 (95% CI 1.78-12.40)
Age, residual pulmonary vascular obstruction, and antiphospholipid antibodies are independent predictors of recurrent VTE after a first unprovoked pulmonary embolism, which may help guide the duration of anticoagulation.
Tromeur et al. (2018) conducted an RCT in unprovoked pulmonary embolism (n=371). warfarin vs. placebo was evaluated on recurrent venous thromboembolism (VTE) (HR 4.70, 95% CI 1.78-12.40). Age >65 years (HR 4.70; 95% CI 1.78-12.40), pulmonary vascular obstruction index ≥5% at 6 months, and antiphospholipid antibodies independently predicted recurrent VTE after unprovoked PE.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: